Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) fell 0.4% on Thursday . The company traded as low as $7.80 and last traded at $7.99. 815 shares changed hands during trading, a decline of 74% from the average session volume of 3,077 shares. The stock had previously closed at $8.0250.
Clinuvel Pharmaceuticals Stock Up 2.5%
The business has a 50 day moving average price of $8.24 and a 200 day moving average price of $7.85.
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Further Reading
- Five stocks we like better than Clinuvel Pharmaceuticals
- NEW LAW: Congress Approves Setup For Digital Dollar?
- The day the gold market broke
- Your Bank Account Is No Longer Safe
- What a Former CIA Agent Knows About the Coming Collapse
- He just nailed another gold prediction …
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
